Biophysical Characterization and Expression Analysis of Kv1.3 Potassium Channel in Primary Human Leukemic B Cells

Cellular Physiology and Biochemistry

Volumn 37, Issue 3, 2020, Pages 965-978

  Szabo, Ildiko ^a   Trentin, Livio ^b   Trimarco, Valentina ^b   Semenzato, Gianpietro ^b   Leanza, Luigi ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

B RAF; Chronic lymphocytic leukemia; Clofazimine; Mesenchymal stromal cell; Potassium channel

Indexed keywords

DOXAZOSIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; POTASSIUM CHANNEL KV1.3; B RAF KINASE; BRAF PROTEIN, HUMAN; CINNAMIC ACID DERIVATIVE; CYCLOPROPANE DERIVATIVE; IGMESINE; INDOLE DERIVATIVE; KCNA3 PROTEIN, HUMAN; SULFONAMIDE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; ELECTROPHYSIOLOGY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MEMBRANE STEADY POTENTIAL; MESENCHYMAL STROMA CELL; PATCH CLAMP TECHNIQUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; DRUG EFFECTS; JURKAT CELL LINE; MEMBRANE POTENTIAL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; B-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CINNAMATES; COCULTURE TECHNIQUES; CYCLOPROPANES; DOXAZOSIN; HUMANS; INDOLES; JURKAT CELLS; KV1.3 POTASSIUM CHANNEL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE POTENTIALS; MESENCHYMAL STROMAL CELLS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES; UP-REGULATION;

EID: 84942274973     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430223     Document Type: Article

References (49)

1. Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A: Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem 2009;16:66-93.
2. Pardo LA, Stuhmer W: The roles of K(+) channels in cancer. Nat Rev Cancer 2014;14:39-48.
3. Lastraioli E, Iorio J, Arcangeli A: Ion channel expression as promising cancer biomarker. Biochim Biophys Acta 2014;pii: S0005-2736(14)00452-0.
4. Urrego D, Tomczak AP, Zahed F, Stuhmer W, Pardo LA: Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond B Biol Sci 2014;369:20130094.
5. Huang X, Jan LY: Targeting potassium channels in cancer. J Cell Biol 2014;206:151-162.
6. Leanza L, O'Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabò I: Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des 2014;20:189-200.
7. Leanza L, Biasutto L, Managò A, Gulbins E, Zoratti M, Szabò I: Intracellular ion channels and cancer. Front Physiol 2013;4:227.
8. Leanza L, Zoratti M, Gulbins E, Szabò I: Mitochondrial ion channels as oncological targets. Oncogene 2014;33:5569-5581.
9. Grossinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, Schmolzer J, Asslaber D, Hainzl S, Neureiter D, Egle A, Pinon-Hofbauer J, Hartmann TN, Greil R, Kerschbaum HH: Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. Leukemia 2014;28:954-958.
10. Arcangeli A, Pillozzi S, Becchetti A: Targeting ion channels in leukemias: A new challenge for treatment. Curr Med Chem 2012;19:683-696.
11. Leanza L, Henry B, Sassi N, Zoratti M, Chandy KG, Gulbins E, Szabò I: Inhibitors of mitochondrial Kv1.3 channels induce Bax/Bak-independent death of cancer cells. EMBO Mol Med 2012;4:577-593.
12. Leanza L, Trentin L, Becker KA, Frezzato F, Zoratti M, Semenzato G, Gulbins E, Szabò I: Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia. Leukemia 2013;27:1782-1785.
13. Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D'Amico M, Basso G, Becchetti A, Campana D, Arcangeli A: Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 2011;117:902-914.
14. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R: Clofazimine: current status and future prospects." J Antimicrob Chemother 2012;67:290-298.
15. Frezzato F, Trimarco V, Martini V, Gattazzo C, Ave E, Visentin A, Cabrelle A, Olivieri V, Zambello R, Facco M, Zonta F, Cristiani A, Brunati AM, Moro S, Semenzato G, Trentin L: Leukaemic cells from chronic lymphocytic leukaemia patients undergo apoptosis following microtubule depolymerization and Lyn inhibition by nocodazole. Br J Haematol 2014;165:659-672.
16. Cahalan MD, Chandy KG: The functional network of ion channels in T lymphocytes. Immunol Rev 2009;231:59-87.
17. Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, Schlichter LC: Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 2002;277:18528-18534.
18. Partiseti M, Choquet D, Diu A, Korn H: Differential regulation of voltage-And calcium-Activated potassium channels in human B lymphocytes. J Immunol 1992;148:3361-3368.
19. Partiseti M, Korn H, Choquet D: Pattern of potassium channel expression in proliferating B lymphocytes depends upon the mode of activation. J Immunol 1993;151:2462-2470.
20. Wulff H, Knaus HG, Pennington M, Chandy KG: K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol 2004;173:776-786.
21. Pahapill PA, Schlichter LC: Modulation of potassium channels in intact human T lymphocytes. J Physiol 1992;445:407-430.
22. Szabò I, Nilius B, Zhang X, Busch AE, Gulbins E, Suessbrich H, Lang F: Inhibitory effects of oxidants on n-Type K+ channels in T lymphocytes and Xenopus oocytes. Pflugers Arch 1997;433:626-632.
23. Birerdinc A, Nohelty E, Marakhonov A, Manyam G, Panov I, Coon S, Nikitin E, Skoblov M, Chandhoke V, Baranova A: Pro-Apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region. Tumour Biol 2010;31:33-45.
24. Staudacher I, Jehle J, Staudacher K, Pledl HW, Lemke D, Schweizer PA, Becker R, Katus HA, Thomas D: HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells. PLoS One 2014;9:e88164.
25. Fuchs O: Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets 2013;13:16-34.
26. Pakladok T, Hosseinzadeh Z, Almilaji A, Lebedeva A, Shumilina E, Alesutan I, Lang F: Up-regulation of hERG K(+) channels by B-RAF. PLoS One 2014;9:e87457.
27. Renaudo A, L'Hoste S, Guizouarn H, Borgese F, Soriani O: Cancer cell cycle modulated by a functional coupling between sigma-1 receptors and Cl-channels. J Biol Chem 2007;282:2259-2267.
28. Renaudo A, Watry V, Chassot AA, Ponzio G, Ehrenfeld J, Soriani O: Inhibition of tumor cell proliferation by sigma ligands is associated with K+ Channel inhibition and p27kip1 accumulation. J Pharmacol Exp Ther 2004;311:1105-1114.
29. Martial S, Giorgelli JL, Renaudo A, Derijard B, Soriani O: SP600125 inhibits Kv channels through a JNKindependent pathway in cancer cells. Biochem Biophys Res Commun 2008;366:944-950.
30. Burger JA, Gribben JG: The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol 2014;24:71-81.
31. Scupoli MT, Pizzolo G: Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. Expert Rev Hematol 2012;5:341-348.
32. Zonta F, Pagano MA, Trentin L, Tibaldi E, Frezzato F, Trimarco V, Facco M, Zagotto G, Pavan V, Ribaudo G, Bordin L, Semenzato G, Brunati AM: Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood 2015; 125:3747-3755.
33. Szabò I, Gulbins E, Apfel H, Zhang X, Barth P, Busch AE, Schlottmann K, Pongs O, Lang F: Tyrosine phosphorylation-dependent suppression of a voltage-gated K+ channel in T lymphocytes upon Fas stimulation. J Biol Chem 1996;271:20465-20469.
34. Roskoski R Jr: ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012;66:105-143.
35. Hosseinzadeh Z, Almilaji A, Honisch S, Pakladok T, Liu G, Bhavsar SK, Ruth P, Shumilina E, Lang F: Upregulation of the large conductance voltage-And Ca2+-Activated K+ channels by Janus kinase 2. Am J Physiol Cell Physiol 2014;306:C1041-1049.
36. Tyan L, Sopjani M, Dermaku-Sopjani M, Schmid E, Yang W, Xuan, Shumilina E, Lang F: Inhibition of voltagegated K+ channels in dendritic cells by rapamycin. Am J Physiol Cell Physiol 2010;299:C1379-1385.
37. Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D: Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Mol Med 2012;18:19-28.
38. Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 2004;5:875-885.
39. Colley BS, Biju KC, Visegrady A, Campbell S, Fadool DA: Neurotrophin B receptor kinase increases Kv subfamily member 1.3 (Kv1.3) ion channel half-life and surface expression. Neuroscience 2007;144:531-546.
40. Ricci A, Bronzetti E, Conterno A, Greco S, Mulatero P, Schena M, Schiavone D, Tayebati SK, Veglio F, Amenta F: Alpha1-Adrenergic receptor subtypes in human peripheral blood lymphocytes. Hypertension 1999;33:708-712.
41. Grisanti LA, Perez DM, Porter JE: Modulation of immune cell function by alpha(1)-Adrenergic receptor activation. Curr Top Membr 2011;67:113-138.
42. Kinoshita M, Matsuoka Y, Suzuki T, Mirrielees J, Yang J: Sigma-1 receptor alters the kinetics of Kv1.3 voltage gated potassium channels but not the sensitivity to receptor ligands. Brain Res 2012;1452:1-9.
43. Crottes D, Martial S, Rapetti-Mauss R, Pisani DF, Loriol C, Pellissier B, Martin P, Chevet E, Borgese F, Soriani O: Sig1R protein regulates hERG channel expression through a post-Translational mechanism in leukemic cells. J Biol Chem 2011;286:27947-27958.
44. Gulbins E, Sassi N, Grassme H, Zoratti M, Szabò I: Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in lymphocytes. Biochim Biophys Acta 2010;1797:1251-1259.
45. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P: Effective elimination of fludarabine-resistant CLL cells by PEITC through a redoxmediated mechanism. Blood 2008;112:1912-1922.
46. Trachootham D, Alexandre J, Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 2009;8:579-591.
47. Gasparoli L, D'Amico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A, Mitcheson JS, Basso G, Becchetti A, Arcangeli A: New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity. Mol Pharmacol 2015;87:183-196.
48. Leanza L, Venturini E, Kadow S, Carpinteiro A, Gulbins E, Becker KA: Targeting a mitochondrial potassium channel to fight cancer. Cell Calcium 2015;58:131-138.
49. Pillozzi S, Gasparoli L, Stefanini M, Ristori M, D'Amico M, Alessio E, Scaletti F, Becchetti A, Arcangeli A, Messori L: NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. Dalton Trans 2014;43:12150-12155.